Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly semaglutide vs insulin aspart three times daily as add-on therapy in type 2 diabetes
2017-003219-20Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003219-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003219-20.